Spécifications
- Antigen name:Palivizumab
- Clonality:Monoclonal
- Clone:2F12
- Conjugation:Unconjugated
- ELISA:Yes
- Host:Mouse
- Isotype:IgG1 kappa
- Size:40 μg
- Cross adsorption:No
- Form:Lyophilized
- Storage buffer:This product is lyophilized with PBS, pH 7.2, containing 0.02% sodium azide
- Storage temperature:The lyophilized product remains stable up to 1 year at −20 °C from date of receipt. Upon reconstitution, it can be stored for 2 - 3 weeks at 2...8 °C or for up to 12 months at −20 °C or below. Avoid repeated freezing and thawing cycles
- Concentration:Reconstitute the lyophilized powder with deionized water (or equivalent) to a final concentration of 0.5 mg/ml.
- Immunogen:Palivizumab
- Cat. no.:77007-564
- Packaging:Vial
Spécifications
À propos de cet article
Palivizumab with trade name Synagis, is an FDA-approved drug for the prevention of respiratory syncytial virus (RSV) infections. It is a recombinant humanized IgG1 kappa isotype monoclonal antibody. Palivizumab binds the RSV envelope fusion protein (RSV F) on the surface of the virus and blocking a critical step in the membrane fusion process. Anti-Palivizumab Antibody (2F12), mAb, Mouse is produced from a hybridoma resulting from the fusion of partner and B-lymphocytes obtained from a mouse immunized with Palivizumab.
- High specificity
- High affinity
- High stability
GenScript has developed a broad range of off-the-shelf anti-idiotype antibodies against blockbuster drugs to help accelerate your research of biosimilars.
Type:
Antigen: Palivizumab
Clonality: Monoclonal
Clone: 2F12
Conjugation:
Epitope:
Host: Mouse
Isotype: IgG1 kappa
Reactivity: